Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,496,514 papers from all fields of science
Search
Sign In
Create Free Account
SAPCD2 gene
Known as:
p42.3
, suppressor APC domain containing 2
, SAPCD2
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Positive relationship between p42.3 gene and inflammation in chronic non‐atrophic gastritis
Ping Chen
,
Yun Cui
,
Qing Yan Fu
,
You-yong Lu
,
J. Fang
,
Xiao Yu Chen
Journal of Digestive Diseases
2015
Corpus ID: 27471965
Gastric cancer (GC) is a typical type of inflammation‐related tumor. The p42.3 gene is shown to be highly expressed in GC, but…
Expand
2015
2015
p 42 . 3 promotes cell proliferation and invasion in human Renal-Cell Carcinoma
Pei-Hua Li
,
Wenjia Cao
,
L. Mao
,
Hui Huang
,
Junnian Zheng
,
D. Pei
2015
Corpus ID: 4845038
p42.3 is a tumor-specific gene and found to be over-expressed in many tumor cell lines and primary tumor tissues. It plays a…
Expand
2013
2013
A DNA vaccine targeting p42.3 induces protective antitumor immunity via eliciting cytotoxic CD8+T lymphocytes in a murine melanoma model
Hu Liu
,
S. Geng
,
+10 authors
Bin Wang
Human Vaccines & Immunotherapeutics
2013
Corpus ID: 23559675
The p42.3 gene was recently identified and characterized as having tumor-specific and mitosis phase-dependent expression in many…
Expand
2013
2013
Sa1694 Low Molecular Weight Protein Tyrosine Phosphatase (LMW-PTP) Is Upregulated in Primary Colorectal Cancer and Affects Cancer Signaling Pathways
E. Hoekstra
,
L. Kodach
,
+4 authors
G. Fuhler
2013
Corpus ID: 58590143
2013
2013
Sa1693 The Role of C9orf140 in Colorectal Cancer Invasion
Yu-rong Weng
,
Jie Hong
,
Yanan Yu
,
L. Ren
,
J. Fang
2013
Corpus ID: 70697916
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE